(MM-121-06-01-06) A Phase I, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination with Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
Title (MM-121-06-01-06) A Phase I, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination with Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
Contact AD
Principal Investigator Grace Dy, MD
Study Number 188110
Phase1
Summary The main purpose of this study is to learn the dose of MM-121 in combination with other anticancer therapies that does not cause unacceptable side effects, or the dose of MM-121 that produces the best drug concentration level in the human body.
Eligibility
Inclusion Criteria:
- Pathologically confirmed advanced-stage solid tumors
- Disease for which the selected combined chemotherapy is indicated or is a reasonable option
- Able to perform daily activities
- Adequate bone marrow, liver, and renal function
Exclusion Criteria:
- Prior radiation therapy to > 25% of bone marrow-bearing areas
- Evidence of any other active malignancy
